• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, September 16, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Lyncean Technologies Inc. closes $13.75 million funding with a syndicate including Intel Capital

Bioengineer by Bioengineer
May 8, 2018
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

FREMONT, CA — Lyncean Technologies, a pioneer in compact accelerator-based light sources for use in industry and academia, has secured $13.75 million in the initial close of a Series B financing round with a syndicate including Intel Capital. The round included participation from current investors EuroUS Ventures AG, Anchor Fund and Quintus Vermoegensverwaltung GmbH. The investment will support development of a novel high power extreme ultraviolet (EUV) source for potential future use in semiconductor manufacturing. Lyncean also will expand manufacturing operations for its Compact Light Source (CLS), a high flux X-ray source that makes synchrotron quality experiments possible in a local laboratory.

"The funding provided by this group of investors reinforces our vision of the Compact Light Source changing the landscape of applied research," said Michael Feser, CEO of Lyncean Technologies. "This new round also enables initial development of an accelerator-based, clean, reliable, high power EUV source for potential use in future lithography systems."

Lyncean Technologies will use the investment to install a Compact Light Source for customer demonstration purposes and to make required personnel investments to develop the EUV source.

"Our investment will help Lyncean grow its business and develop its extreme ultraviolet technology," said Wendell Brooks, senior vice president of Intel Corporation and president of Intel Capital. "We are glad to support innovative approaches to semiconductor manufacturing that support the continuation of Moore's Law."

###

About Lyncean Technologies

Lyncean Technologies, Inc. was founded in 2001 to develop the Compact Light Source (CLS), a miniature synchrotron X-ray source based on research performed at the SLAC National Accelerator Laboratory and Stanford University. The CLS replaces the conventional "undulator" magnets in large synchrotrons via laser technology, which scales down the entire device by a factor of 200 to provide industrial and academic customers a home solution for state-of-the-art X-ray needs. Lyncean's newest development is a novel EUV source based on coherent photon generation in a compact electron storage ring, specifically designed for high volume manufacturing semiconductor lithography. For more information visit: http://www.lynceantech.com

About Intel Capital

Intel Capital invests in innovative startups targeting artificial intelligence, autonomous driving, workload accelerators, 5G connectivity, virtual reality and a wide range of other disruptive technologies. Since 1991, Intel Capital has invested $12.3 billion in 1,530 companies worldwide, and more than 660 portfolio companies have gone public or been acquired. Intel Capital curates thousands of business development introductions each year between its portfolio companies and the Global 2000. For more information on what makes Intel Capital one of the world's most powerful venture capital firms, visit http://www.intelcapital.com or follow @Intelcapital.

Media Contact

Jack Kasahara
[email protected]
408-838-6034

http://www.lynceantech.com

Share12Tweet7Share2ShareShareShare1

Related Posts

Shifts in Infective Endocarditis Demographics: 2012-2021

September 16, 2025

Assessing Disability: WHO vs. Daily Living Scales

September 16, 2025

Practical Skin Care Tips for 22–24 Week Infants

September 16, 2025

TUG1 Suppression Boosts Immunity and Lenvatinib in Liver Cancer

September 16, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    154 shares
    Share 62 Tweet 39
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    116 shares
    Share 46 Tweet 29
  • Physicists Develop Visible Time Crystal for the First Time

    66 shares
    Share 26 Tweet 17
  • A Laser-Free Alternative to LASIK: Exploring New Vision Correction Methods

    49 shares
    Share 20 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Shifts in Infective Endocarditis Demographics: 2012-2021

Assessing Disability: WHO vs. Daily Living Scales

Creating a Sulfur Vacancy Redox Disruptor for Innovative Therapies Targeting Cuproptosis, Ferroptosis, and Apoptosis through Photothermoelectric and Cascade Catalytic Mechanisms

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.